遠大醫藥(00512.HK)創新藥STC3141內地臨床試驗完成首例患者給藥
遠大醫藥(00512.HK)公布,附屬Grand Medical Pty Ltd正在開發的用於治療急性呼吸窘迫綜合症(ARDS)的全球創新藥物STC3141,在中國開展的Ib期臨床試驗已完成首例患者給藥。
此次STC3141在中國開展的治療ARDS患者的Ib期臨床試驗,旨在研究和評估藥物在治療ARDS患者中的安全性、耐受性和代謝特性,積累更多資料綜合評估後期臨床試驗的風險和效益,以加快產品的全球開發進程。
公司表示,針對尚未滿足的臨床需求,未來將加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.